Project Description

molecular partners

CEO: Patrick Amstutz

Sector: Biotech
Location: Zurich, Switzerland
Investment Stage: Start up
Investment Status: IPO in 2014
Year Invested: 2007

Molecular Partners

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange.

See Molecular Partners related news here

Back to all companies